Form D · Biotechnology
Applied Therapeutics, Inc.
New York, NY · CIK 0001697532
Offering snapshot reported Mar 13, 2024 · SEC filing
- Reported sold
- $100M Offering amount: $100M
- Investors reported
- 31 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 27, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 13, 2024 | Initial | $99,997,998 | No comparison | 31 | SEC filing |
| May 5, 2023 | Initial | $30,000,002 | No comparison | 19 | SEC filing |
| Nov 21, 2019 | Initial | $20,014,988 | No comparison | 12 | SEC filing |
| Nov 19, 2018 | Initial | $27,158,092 | No comparison | 37 | SEC filing |
| Feb 20, 2018 | Initial | $6,000,000 | No comparison | 23 | SEC filing |
| Feb 8, 2017 | Initial | $6,067,875 | No comparison | 26 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $7.5M (estimated)
- Finders' fees
- $0
- Form D file number
- 021-507505
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| UBS Securities LLC | 7654 | |
| Leerink Partners LLC | 39011 | |
| RBC Capital Markets, LLC | 31194 | |
| Robert W. Baird & Co. Inc. | 8158 |
Source: Form D, filed Mar 13, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Franklin Berger | Director |
| Les Funtleyder | Director, Executive |
| Adam Hansard | Executive |
| Stacy J. Kanter | Director |
| Teena Lerner | Director |
| Joel S. Marcus | Director |
| Riccardo Perfetti | Executive |
| Shoshana Shendelman | Director, Executive |
| Jay S. Skyler | Director |
| Catherine Thorpe | Executive |
| Mark Vignola | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
545 Fifth Avenue, Suite 1400
New York, NY, 10017
New York, NY, 10017